Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
FZ.2ENiu-ECACGTTAACAATATTGCAGC20402639126372R-20723.8China
FZ.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FY.4ORF1abPasteur-ORF1ab-2CTGGTCAAGGTTAATATAGG20401418614167R-18348.8France
FY.4ENiu-ETTCTTGCTTTCGTGGTATTC20402630326322F-19913.4China
FY.4ENiu-ECACGTTAACAATATTGCAGC20402639126372R-20723.8China
FY.4NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.497ORF1abPasteur-ORF1ab-2CTGGTCAAGGTTAATATAGG20401418614167R-18348.8France
B.1.497ENiu-ETTCTTGCTTTCGTGGTATTC20402630326322F-19913.4China
B.1.497ENiu-ECACGTTAACAATATTGCAGC20402639126372R-20723.8China
B.1.497NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-17121.6US
EN.1.1ORF1abPasteur-ORF1ab-2CTGGTCAAGGTTAATATAGG20401418614167R-18348.8France
EN.1.1ENiu-ETTCTTGCTTTCGTGGTATTC20402630326322F-19913.4China
EN.1.1ENiu-ECACGTTAACAATATTGCAGC20402639126372R-20723.8China
EN.1.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.30 (Delta)ORF1abPasteur-ORF1ab-2CTGGTCAAGGTTAATATAGG20401418614167R-18348.8France
AY.30 (Delta)ENiu-ETTCTTGCTTTCGTGGTATTC20402630326322F-19913.4China
AY.30 (Delta)ENiu-ECACGTTAACAATATTGCAGC20402639126372R-20723.8China
AY.30 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.85 (Delta)ORF1abPasteur-ORF1ab-2CTGGTCAAGGTTAATATAGG20401418614167R-18348.8France
AY.85 (Delta)ENiu-ETTCTTGCTTTCGTGGTATTC20402630326322F-19913.4China
AY.85 (Delta)ENiu-ECACGTTAACAATATTGCAGC20402639126372R-20723.8China
AY.85 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.6.1ORF1abPasteur-ORF1ab-2CTGGTCAAGGTTAATATAGG20401418614167R-15038.3France
XBB.6.1ENiu-ETTCTTGCTTTCGTGGTATTC20402630326322F-19913.4China
XBB.6.1ENiu-ECACGTTAACAATATTGCAGC20402639126372R-20723.8China
XBB.6.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BF.21ORF1abPasteur-ORF1ab-2CTGGTCAAGGTTAATATAGG20401418614167R-18348.8France
BF.21ENiu-ETTCTTGCTTTCGTGGTATTC20402630326322F-19913.4China
BF.21ENiu-ECACGTTAACAATATTGCAGC20402639126372R-20723.8China
BF.21NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FK.1.3.2ORF1abPasteur-ORF1ab-2CTGGTCAAGGTTAATATAGG20401418614167R-18348.8France
FK.1.3.2ENiu-ETTCTTGCTTTCGTGGTATTC20402630326322F-19913.4China
FK.1.3.2ENiu-ECACGTTAACAATATTGCAGC20402639126372R-20723.8China
FK.1.3.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBFORF1abPasteur-ORF1ab-2CTGGTCAAGGTTAATATAGG20401418614167R-18348.8France
XBFENiu-ETTCTTGCTTTCGTGGTATTC20402630326322F-19913.4China
XBFENiu-ECACGTTAACAATATTGCAGC20402639126372R-20723.8China
XBFNUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.5.6ORF1abPasteur-ORF1ab-2CTGGTCAAGGTTAATATAGG20401418614167R-18348.8France
BA.5.6ENiu-ETTCTTGCTTTCGTGGTATTC20402630326322F-19913.4China
BA.5.6ENiu-ECACGTTAACAATATTGCAGC20402639126372R-20723.8China
BA.5.6NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BF.11.5ORF1abPasteur-ORF1ab-2CTGGTCAAGGTTAATATAGG20401418614167R-18348.8France
BF.11.5ENiu-ETTCTTGCTTTCGTGGTATTC20402630326322F-19913.4China
BF.11.5ENiu-ECACGTTAACAATATTGCAGC20402639126372R-20723.8China
BF.11.5NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBF.7.1ORF1abPasteur-ORF1ab-2CTGGTCAAGGTTAATATAGG20401418614167R-18348.8France
XBF.7.1ENiu-ETTCTTGCTTTCGTGGTATTC20402630326322F-1427.97China
XBF.7.1ENiu-ECACGTTAACAATATTGCAGC20402639126372R-20723.8China
XBF.7.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used